ENTITY
RemeGen

RemeGen (9995 HK)

293
Analysis
Health CareChina
RemeGen is a China-based biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on therapeutic antibody drugs, including antibody-drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies, for major diseases such as autoimmune disorders, oncology, and ophthalmology. Key products include Telitacicept (RC18) and Disitamab Vedotin (RC48). RemeGen was co-founded in 2008 and is headquartered in Yantai, Shandong Province, China.
more
27 Apr 2026 23:18

Mabwell (迈威生物) A+H IPO Trading

​Mabwell A+H is set to start trading on April 28. We update deal dynamics, recap valuation, and reference peers. We think the deal will be...

Logo
187 Views
Share
15 May 2024 16:01

[Blue Lotus Daily]:9926 HK/1801HK/ BGNE/9995HK/ZLAB/NIO/LI/1211HK/BEKE/1810HK/3888HK/981HK/MSFT/INTC

​US Biosecure Act extends Chinese collaboration until 2032, BeiGene and Zai Lab exceed Q1 expectations with BRUKINSA and Efgartigimod.

Share
26 Apr 2024 20:42

[Blue Lotus Daily]:9926HK/1801HK/BGNE US/9995HK/LI US/1810HK/1211HK/NIO US/XPEVUS/300274SZ/ 300750SZ

Stablization of insulin NDRL price suspected major changes.  New energy exports were generally weak in March, with new energy vehicles thriving....

Share
17 Apr 2024 18:29

[Blue Lotus Daily]:1810 HK/HTHT US/ATAT US/300750 SZ/9995 HK

​Xiaomi's SU7 orders exceed 60K, Orange Crystal Hotel aims for 750 locations by 2025, GAC to mass produce all-solid-state batteries by 2026.

Share
10 Apr 2024 16:46

[Blue Lotus Daily]:XPEV/1211 HK/3759HK/1548HK/9926HK/BGNE/9995HK/1801 HK/1810HK/LKNCY/LI/NIO/MNSO US

​Didi and GAC Aion to launch first commercial L4 model in 2025, US biologic drug ban could benefit Chinese innovative drug companies, Xiaomi SU7...

Share
x